Over 1,500,000 new cancer cases and over 570,000 deaths from cancer are projected to occur in the U.S. in 2011.
Learn how the Serum HER-2/neu test can indicate whether metastatic breast cancer is progressing or responding to treatment.
Learn about two approaches for addressing prostate cancer specificity challenges associated with PSA testing.
Siemens is committed to transforming cancer care by bringing together in vivo imaging technologies with in vitro diagnostics (IVD) through innovative information technology. Our goal is to provide integrated, performance-driven oncology solutions that improve patient outcomes, optimize clinical workflow, and bring personalized medicine to patients around the world.